Expert consensus on quality control for detecting autoantibodies.
10.3760/cma.j.cn112138-20230619-00320
- Collective Name:National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital); Experimental Diagnosis Research Committee;Rheumatology and Immunology Physicians Committee of Chinese Medical Doctor Association, Autoantibodies Detection Committee;Chinese Rheumatism Data Center
- Publication Type:Journal Article
- MeSH:
Humans;
Autoantibodies;
Consensus;
Autoimmune Diseases/diagnosis*;
Quality Control;
Reference Standards
- From:
Chinese Journal of Internal Medicine
2023;62(12):1418-1422
- CountryChina
- Language:Chinese
-
Abstract:
Autoantibodies are important biomarkers of autoimmune diseases and crucial for disease diagnosis, differential diagnosis, and the evaluation of disease activity and prognosis. Specifying the requirement of quality control for detecting autoantibodies is essential for accurately reporting relevant results. In 2023, National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), Experimental Diagnosis Research Committee, Rheumatology and Immunology Physicians Committee of Chinese Medical Doctor Association, Autoantibodies Detection Committee, Chinese Rheumatism Data Center invited relevant clinical and laboratory experts to develop the current consensus based on the national standards, the industry guidelines, the national situation, and the experience of quality control regarding autoantibody detection. This consensus aims to standardize the quality control of autoantibody detection in relevant laboratories in China.
